Thomas J. Coates

Lo que funciona en la prevención

Si sabemos lo que funciona al prevenir el VIH — ¿porqué no sacamos mayor provecho?

¿qué hemos aprendido?

Hace quince años, en Los Angeles, CA, se diagnosticaron los primeros 5 casos de SIDA entre hombres homosexuales. Desde entonces el SIDA se ha extendido a más de medio millón de personas en los EEUU y actualmente es la causa líder de muertes entre los Norteamericanos de 25 a 44 años de edad. Estos quince años han sido testigos del gran avance logrado tratando de entender como detener esta enfermedad.

What works in HIV prevention

We Know What Works in HIV Prevention -Why Aren’t We Doing More of It?

What have we learned?

Fifteen years ago, the first AIDS cases were diagnosed among 5 gay men in Los Angeles, CA. Since then, AIDS has spread to over half a million people in the US and is the leading cause of death for all Americans aged 25-44. Fifteen years have also seen great leaps in understanding how to prevent the spread of HIV. But these fifteen years have not seen the widespread implementation of effective HIV prevention programs in the US.

Prevención Posexposición

¿Que es la prevención pos-exposición (PEP)?

¿por qué PEP ahora?

Aún no se descubre la cura del SIDA. La prevención continúa siendo la mejor forma de detener esta epidemia. La mejor forma de no contraer el VIH es evitando la exposición en primer lugar: abstinerse sexualmente, tener solo parejas sanas, hacer uso constante del condón, abstenerse de usar drogas inyectables y la esterilización constante del equipo de inyeción.1 Recientemente hemos aprendido mucho sobre el tratamiento del VIH y la progresión de la misma.

Post-exposure prevention (PEP)

What Is Post-Exposure Prevention (PEP)?

Why PEP now?

There is still no cure for AIDS. Prevention remains the most effective way to halt the epidemic. The best way to avoid HIV infection is to avoid exposure in the first place through sexual abstinence, having only uninfected sex partners, consistent condom use, injection drug use abstinence, and consistent use of sterile injection equipment.1 However, recently we have learned a lot about treating HIV and understanding the progression of HIV disease.

The Voluntary HIV-1 Counseling and Testing Efficacy Study: A Randomized Controlled Trial in Three Developing Countries

The Voluntary HIV-1 Counseling and Testing Efficacy Study was designed to measure the efficacy of HIV VCT in developing country and resource poor settings where access to antiretrovirals and other expensive medications is difficult or impossible.

Motivators and Barriers To Use Of Combination Therapies In Patients With HIV Disease

The successful two-drug combination therapy in 1994 and protease inhibitors in 1995 set the stage for a new era in treatment of HIV disease, creating a burst of optimism over the prospect that HIV might be a controllable disease. Initial studies of protease containing triple-drug regimens suggested that these combinations could, in some cases, slow clinical progression of the disease and prolong the lives of patients.

Designing Primary Prevention for People Living with HIV

This monograph is based largely on presentations and discussion at the June, 1999 policy forum Primary HIV Prevention: Designing Effective Programs for People Living with HIV. The Forum was hosted by the AIDS Research Institute at UCSF and the National Association of People with AIDS. The Forum was sponsored by the National Institute of Mental Health (NIMH), the NIH Office of AIDS Research (OAR), and the Centers for Disease Control and Prevention (CDC).

Discovering Global Success: Future Directions for HIV Prevention in the Developing World

The National Institutes of Health’s Fogarty International Center in collaboration with a number of other agencies sponsored the Fogarty Workshop on International HIV/AIDS Prevention Research Opportunities on April 18-20, 1998. The AIDS Research Institute at the University of California, San Francisco hosted the Workshop. The purpose of the workshop was to identify a package of effective HIV prevention interventions and develop a list of priority research goals that combine biomedical, behavioral and social interventions for HIV prevention in developing countries.